Browsing Tag
danicamtiv
2 posts
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
Bristol Myers Squibb to acquire MyoKardia for $13.1bn: A strategic move to strengthen cardiovascular portfolio
Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has announced an agreement to acquire MyoKardia, a California-based…